Update on safety issues related to antihyperglycemic therapy

Diabetes Spectrum

Volumn 27, Issue 2, 2014, Pages 92-100

  Carpio, Gandahari Rosa A ^a   Fonseca, Vivian A ^a  

^a TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BROMOCRIPTINE; CANAGLIFLOZIN; CHLORPROPAMIDE; COLESEVELAM; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INCRETIN; INSULIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TROGLITAZONE; UNINDEXED DRUG; VILDAGLIPTIN;

ABDOMINAL PAIN; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; BLADDER CANCER; CARDIOTOXICITY; CYANOCOBALAMIN DEFICIENCY; DIABETIC PATIENT; DIARRHEA; DIZZINESS; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FLATULENCE; FRACTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; INSULIN DEPENDENT DIABETES MELLITUS; JAUNDICE; LACTIC ACIDOSIS; LEUKOPENIA; LIPODYSTROPHY; LIPOHYPERTROPHY; LIVER DYSFUNCTION; LIVER TOXICITY; MYCOSIS; NAUSEA; NEUTROPHILIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PERIPHERAL EDEMA; POSTMARKETING SURVEILLANCE; REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TASTE DISORDER; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN;

EID: 84901934544     PISSN: 10409165     EISSN: 19447353     Source Type: Journal    
DOI: 10.2337/diaspect.27.2.92     Document Type: Review

References (77)

1. Centers for Disease Control and Prevention: National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, Ga., U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
2. American Diabetes Association: Economic costs of diabetes in the U.S. in 2012. Diabetes Care 36 (Suppl. 4):S1033-S1046, 2013
3. American Diabetes Association: Standards of medical care in diabetes - 2014. Diabetes Care 37 (Suppl. 1):S14-S80, 2014
4. Gan SC, Barr J, Arieff AI, Pearl RG: Biguanide-associated lactic acidosis: case report and review of the literature. Arch Intern Med 152:2333-2336, 1992
5. Pearlman BL, Fenves AZ, Emmett M: Metformin-associated lactic acidosis. Am J Med 101:109-110, 1996 (Pubitemid 26285949)
6. Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S; DREAM Investigators: Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) study. Diabetes Care 33:2250-2253, 2010
7. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM: Williams Textbook of Endocrinology. 12th ed. Philadelphia, Pa., Elsevier Saunders, 2011
8. Dandona P, Fonseca V, Mier A, Beckett AG: Diarrhea and metformin in a diabetic clinic. Diabetes Care 6:472-474, 1983 (Pubitemid 13005555)
9. Harrigan RA, Nathan MS, Beattie P: Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emerg Med 38:68-78, 2001 (Pubitemid 32606034)
10. Melander A: Oral antidiabetic drugs: an overview. Diabet Med 13:143-147, 1996
11. Stang M, Wysowki DK, Butler-Jones D: Incidence of lactic acidosis in metformin users. Diabetes Care 22:925-927, 1999 (Pubitemid 29241046)
12. Gardner DG, Shoback D: Greenspan's Basic and Clinical Endocrinology. 9th ed. Chicago, Mcgraw Hill, 2011
13. Chang CT, Chen YC, Fang JT, Huang CC: Metformin-associated lactic acidosis: case reports and literature review. J Nephrol 15:398-402, 2002
14. Parra D, Legreid AM, Beckey NP, Reyes S: Metformin monitoring and change in serum creatinine levels in patients undergoing radiologic procedures involving administration of intravenous contrast media. Pharmacotherapy 24:987-993, 2004 (Pubitemid 39025198)
15. Thomsen HS, Morcos SK: Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. ESUR Contrast Media Safety Committee. Eur Radiol 9:738-740, 1999
16. Stacul F, van der Molen A, Reimer P, Webb JA, Thomsen HS, Morcos SK, Almén T, Aspelin P, Bellin MF, Clement O, Heinz-Peer G; Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR): Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 21:2527-2541, 2011
17. Sayer JA: Acute renal failure from contrast medium: beware patients taking metformin. BMJ 333:653, 2006
18. Yale JF: Oral antihyperglycemic agents and renal disease: new agents, new concepts. J Am Soc Nephrol 16:S7-S10, 2005
19. 12 malabsorption induced by metformin. Diabetes Care 23:1227-1231, 2000
20. 12 supplements: the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care 35:2327-2333, 2012
21. Fonseca VA, Lavery LA, Thethi TK: Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. AJM 126:141-149, 2013
22. Marcy TR, Britton ML, Blevins SM: Second-generation thiazolidinediones and hepatotoxicity. Ann Pharmacother 38:1419-1423, 2004 (Pubitemid 39100194)
23. Asnani S, Richard BC, Desouza C, Fonseca V: Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet. Curr Med Res Opin 19:609-613, 2003 (Pubitemid 37288067)
24. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A; PROactive Study Group: The prospective pioglitazone clinical trial in macrovascular events (PROactive). Diabetes Care 27:1647-1653, 2004
25. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV; RECORD Study Team: Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125-2135, 2009
26. McGuire DK, Inzucchi SE: New drugs for the treatment of diabetes mellitus part 1: thiazolidinediones and their evolving cardiovascular implications. Circulation 117:440-449, 2008
27. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11:861-866, 2005 (Pubitemid 41161118)
28. Berlie HD, Kalus JS, Jaber LA: Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract 76:279-289, 2007 (Pubitemid 46400130)
29. Singh S, Loke YK, Furberg CD: Thiazolidinediones and heart failure: a teleoanalysis. Diabetes Care 30:2148-2153, 2007
30. Nesto RW, Bell D, Bonow RO, Fonseca VA, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R: Thiazolidinedione use, fluid retention and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27:1256-1263, 2004
31. Toprani A, Fonseca VA: Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes. Diabetes Obes Metab 13:276-280, 2011
32. Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK: Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 95:592-600, 2010
33. Aubert RE, Herrerra V, Chen W, Haffner SM, Pendergrass M: Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab 12:716-721, 2010
34. Kahn SE, Zinman B, Lachin JM: Rosiglitazone-associated fractures in type 2 diabetes. Diabetes Care 31:845-851, 2008
35. Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW: Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus. Drug Saf 32:675-690, 2009
36. Colmers IN, Bowker SL, Majumdar SR, Johnson JA: Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 184:e675-e683, 2012
37. Piccinni C, Motola D, Marchesini G, Poluzzi E: Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 34:1369-1371, 2011
38. Azoulay L, Lin H, Filion KB, Assayag J, Majdan A, Pollak MN, Suissa S: The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 344:e3645, 2012
39. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL: Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34:916-922, 2011
40. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H: Pioglitazone and risk of bladder cancer among diabetic patients in France: a population based cohort study. Diabetologia 55:1953-1962, 2012
41. Zhu Z, Shen Z, Lu Y, Zhong S, Xu C: Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 98:159-163, 2012
42. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572, 2008
43. Rodgers NW: Sulfonylureas and heart disease in diabetes management. Diabetes Spectrum 12:95-97, 1999
44. Harrower ADB: Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf 22:313-320, 2000
45. Kadowaki T, Hagura R, Kajinuma H, Kuzuya N, Yoshida S: Chlorpropamide-induced hyponatremia: incidence and risk factors. Diabetes Care 6:468-471, 1983 (Pubitemid 13005554)
46. Weissman PN, Shenkman P, Gregerman RI: Chlorpropamide hyponatremia: drug-induced inappropriate antidiuretic hormone activity. N Engl J Med 284:65-71, 1971
47. Campbell RK: Glimepiride: role of new sulfonylureas in the treatment of type 2 diabetes mellitus. Ann Pharmacother 32:1044-1052, 1998
48. Buse JB, Nauck M, Fort T, Sheu WHH, Shenouda SK, Heilmann CR, Hoogwerf BJ, Gao A, Boardman MK, Fineman M, Porter L, Schernthaner G: Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomized open-label study. Lancet 381:117-124, 2012
49. Aroda VR, Ratner R: The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev 27:528-542, 2011
50. Thethi T, Fonseca V: Comparing diabetes drugs: helping clinical decisions? Lancet 381:93-94, 2013
51. Ahmad SR, Swann J: Exenatide and rare adverse events. N Engl J Med 358:1970-1971, 2008 (Pubitemid 351620133)
52. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB: The safety of incretin-based therapies: review of the scientific evidence. J Clin Endocrinol Metab 96:2027-2031, 2011
53. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB: Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33:428-433, 2010
54. Yoon NM, Cavaghan MK, Brunelle RL, Roach P: Exenatide added to insulin therapy: a retrospective review of clinical practice over 2 years in an academic endocrinology outpatient setting. Clin Ther 31:1511-1523, 2009
55. Pendergrass M, Fenton C, Haffner SM, Chen W: Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metab 14:596-600, 2012
56. Parks M, Rosebraugh C: Weighing risks and benefits of liraglutidez: the FDA's review of a new antidiabetic therapy. N Engl J Med 362:774-777, 2010
57. Alves C, Batel-Marques F, Macedo AF: A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 98:271-284, 2012
58. Knudsen LB, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, Mølck AM, Nielsen HS, Nowak J, Solberg H, Thi TDL, Zdravkovic M: Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151:1473-1486, 2010
59. Desai S, Brinker A, Swann J, Iyasu S: Sitagliptin-associated drug allergy: review of spontaneous adverse events reports. Arch Intern Med 170:1169-1171, 2010
60. Hollander P, Li J, Allen E, Chen R, CV181-013 Investigators: Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 94:4810-4819, 2009
61. Balfour JA, McTavish D: Acarbose. Drugs 46:1025-1054, 1993
62. Phillips BB: Managing therapy and adverse effects with antihyperglycemic agents: a focus on metformin and acarbose. In Managing the Patient with Type II Diabetes. Wilson AL, Mehra IV, Eds. Gaithersburg, Md., Aspen Publications, 1997, p. 73-76
63. Andrade RJ, Lucena M, Vega JL, Torres M, Salmeron FJ, Bellot V, Garcia-Escano MD, Moreno P: Acarbose-associated hepatotoxicity. Diabetes Care 21:2029-2030, 1998
64. Hsiao SH, Liao LH, Cheng PN, Wu TJ: Hepatotoxicity associated with acarbose therapy. Ann Pharmacother 40:151-154, 2006
65. Yee HS, Fong NT: A review of the safety and efficacy of acarbose in diabetes mellitus. Pharmacotherapy 16:792-805, 1996 (Pubitemid 26322183)
66. Segal P, Feig PU, Schernthaner G, Ratzmann KP, Rybka J, Petzinna D, Berlin C: The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 20:687-691, 1997 (Pubitemid 27202513)
67. Hirsch IB, Bergenstal IM, Parkin CG, Wright E Jr, Buse JB: A real-world approach to insulin therapy in primary care practice. Clinical Diabetes 23:78-86, 2005 (Pubitemid 40965048)
68. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, Sawicki PT: Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732-1744, 2009
69. Musso G, Gambino R, Cassader M, Pagano G: A novel approach to control hyperglycemia in type 2 diabetes: sodium-glucose co-transport (SGLT) inhibitors, systematic review and meta-analysis of randomized trials. Ann Med 44:375-393, 2012
70. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11:43, 2013
71. Nyirjesy P, Zhao Y, Ways K, Usiskin K: Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 28:1173-1178, 2012
72. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W; Canagliflozin DIA 2001 Study Group: Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35:1232-1238, 2012
73. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR: Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31:1479-1484, 2008
74. Fonseca VA, Handelsman Y, Staels B: Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab 12:384-392, 2010
75. Daiichi Sankyo: Welchol package insert. Parsippany, N.J., Daiichi Sankyo, 2013
76. Gaziano JM, Cincotta AH, O'Connor CM: Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 33:1503-1508, 2010
77. VeroScience: Cyclomet package insert. Tiverton, R.I., VeroScience, 2010